Oct 10 (Reuters) - Lipocine Inc :
* LIPOCINE INC: ANNOUNCES POSITIVE ORAL BREXANOLONE QEEG RESULTS
* LIPOCINE INC: PHASE 1 STUDY EVALUATED QEEG CHANGES IN HEALTHY POSTMENOPAUSAL FEMALES
* LIPOCINE INC: ORAL BREXANOLONE WELL-TOLERATED WITH MINIMAL CNS DEPRESSANT EFFECTS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.